Evidence map›Paper›PMID 42691941›Full record

ArticleJACC. Advances2026

Circulating Levels of Inorganic Pyrophosphate Influence the Risk and Clinical Outcomes in Calciphylaxis.

Sagar U Nigwekar, Api Chewcharat, Kevin O'Brien, Enock Arthur, Jennifer Howe, Lisa Laurion, Hervé Husson, Houda Bouchouari, Aaron Seto, Yves Sabbagh

Abstract read
In one paragraph

Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sagar U NigwekarDivision of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. Electronic address: snigwekar@mgh.harvard.edu.
Api ChewcharatDivision of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Kevin O'BrienResearch and Development, Inozyme Pharma Inc, Boston, Massachusetts, USA.
Enock ArthurDivision of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA; Frank H. Netter MD School of Medicine, Quinnipiac University, North Haven, Connecticut, USA.
Jennifer HoweResearch and Development, Inozyme Pharma Inc, Boston, Massachusetts, USA.
Lisa LaurionResearch and Development, Inozyme Pharma Inc, Boston, Massachusetts, USA.
Hervé HussonResearch and Development, Inozyme Pharma Inc, Boston, Massachusetts, USA.
Houda BouchouariDivision of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Aaron SetoDivision of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA; Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
Yves SabbaghResearch and Development, Inozyme Pharma Inc, Boston, Massachusetts, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

calcific uremic arteriolopathydialysisend-stage kidney diseasepain

Identifiers

PMID42691941
PMCPMC13571338

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.